BackReShape Lifesciences Overview

ReShape Lifesciences Total Current Liabilities

Track ReShape Lifesciences's total current liabilities ($2.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$2.14M
48.00% YoYΔ $-1.98M vs prior year quarter

Peer average

Loading

ReShape Lifesciences Total Current Liabilities History

Loading

ReShape Lifesciences vs. peers: Total Current Liabilities Comparison

Loading

ReShape Lifesciences Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ReShape Lifesciences (RSLS) FAQ

As of the most recent data (March 2026), RSLS shows a total current liabilities of $2.1M. That compares with $4.1M in the prior-year period — down 48.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RSLS's total current liabilities is now $2.1M (was $4.1M) — a 48.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ReShape Lifesciences is outperforming or lagging.

Tracking RSLS's total current liabilities over time shows whether ReShape Lifesciences is scaling, shrinking, or reshaping that part of the business. The current reading is $2.1M That compares with $4.1M in the prior-year period — down 48.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has ReShape Lifesciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $2.1M) with ownership activity and broader fundamentals.

ReShape Lifesciences's total current liabilities is $2.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.